Assessing the IFN signaling patterns in peripheral blood T cells from melanoma patients from Day 0 to Day 29 HDI therapy may be a clinically useful approach to select patients who would be more inclined to benefit from further treatment, and hence should be maintained on HDI. The gene discussed is IFNA1; the disease is melanoma.